An operational comparative study of quinine and artesunate for the treatment of severe malaria in hospitals and health centres in the Democratic Republic of Congo: the MATIAS study

Giovanfrancesco Ferrari, Henry M Ntuku, Christian Burri, Antoinette K Tshefu, Stephan Duparc, Pierre Hugo, Didier K Mitembo, Amanda Ross, Philippe L Ngwala, Joseph N Luwawu, Papa N Musafiri, Symphorien E Ngoie, Christian Lengeler, Giovanfrancesco Ferrari, Henry M Ntuku, Christian Burri, Antoinette K Tshefu, Stephan Duparc, Pierre Hugo, Didier K Mitembo, Amanda Ross, Philippe L Ngwala, Joseph N Luwawu, Papa N Musafiri, Symphorien E Ngoie, Christian Lengeler

Abstract

Background: The Democratic Republic of the Congo (DRC) has the highest number of severe malaria cases in the world. In early 2012, the National Malaria Control Programme (NMCP) changed the policy for treating severe malaria in children and adults from injectable quinine to injectable artesunate. To inform the scaling up of injectable artesunate nationwide, operational research is needed to identify constraints and challenges in the DRC's specific setting.

Methods: The implementation of injectable quinine treatment in 350 patients aged 2 months or older in eight health facilities from October 2012 to January 2013 and injectable artesunate in 399 patients in the same facilities from April to June 2013 was compared. Since this was an implementation study, concurrent randomized controls were not possible. Four key components were evaluated during each phase: 1) clinical assessment, 2) time and motion, 3) feasibility and acceptability, and 4) financial cost.

Results: The time to discharge was lower in the artesunate (median=2, 90% central range 1-9) compared to the quinine group (3 (1-9) days; p<0.001). Similarly, the interval between admission and the start of intravenous (IV) treatment (2 (0-15) compared to 3 (0-20) hours; p<0.001) and parasite clearance time (23 (11-49) compared to 24 (10-82) hours; p<0.001) were lower in the artesunate group. The overall staff pre-administration time (13 (6-38) compared to 20 (7-50) minutes; p<0.001) and the personnel time spent on patient management (9 (1-24) compared to 12 (3-52) minutes; p<0.001) were lower in the artesunate group. In hospitals and health centres, the mean (standard deviation, SD) total cost per patient treated for severe malaria with injectable artesunate was USD 51.94 (16.20) and 19.51 (9.58); and USD 60.35 (17.73) and 20.36 (6.80) with injectable quinine.

Conclusions: This study demonstrates that injectable artesunate in the DRC is easier to use and it costs less than injectable quinine. These findings provide the basis for practical recommendations for rapid national deployment of injectable artesunate in the DRC.

Trial registration: ClinicalTrials.gov NCT01828333.

Figures

Fig. 1
Fig. 1
Map showing the location of the study sites and the selected health zones

References

    1. WHO . World malaria report. Geneva: World Health Organization; 2011.
    1. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376:1647–57. doi: 10.1016/S0140-6736(10)61924-1.
    1. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366:717–25. doi: 10.1016/S0140-6736(05)67176-0.
    1. WHO . Guidelines for the Teatment of Malaria. 2nd edition − Rev. 1. Geneva: World Health Organization; 2011.
    1. WHO . Management of severe malaria − A practical handbook. 3. Geneva: World Health Organization; 2013.
    1. PNLP . Directives nationales de traitement du paludisme en République Démocratique du Congo (Draft) Kinshasa: Ministère de la Santé; 2012.
    1. PNLP. Guide technique de formation en prevention et prise en charge du paludisme (Hopital General de reference). RDC.
    1. World Health Organization Public Assessment Reports (WHOPARs). [].
    1. Medicines for Malaria Venture. [].
    1. CDC Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria-worldwide, 2010–2012. MMWR. 2013;62:5–8.
    1. Burri C, Ferrari G, Ntuku HM, Kitoto AT, Duparc S, Hugo P, et al. Delayed anemia after treatment with injectable artesunate in the democratic republic of the congo: a manageable issue. Am J Trop Med Hyg. 2014;91:821–3. doi: 10.4269/ajtmh.14-0149.
    1. OANDA. Currency converter. [accessed 07 August 2014].
    1. MSH (Management Sciences for Health) International Drug Price Indicator Guide, 2013 Edition. Medford: Mass: MSH; 2014.
    1. WHO . Guidelines for the treatment of malaria. 2. Geneva: World health Organization; 2010.
    1. Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E, et al. Cost-effectiveness of artesunate for the treatment of severe malaria. Trop Med Int Health. 2009;14:332–7. doi: 10.1111/j.1365-3156.2009.02227.x.
    1. Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein L, Mokuolu OA, Nansumba M, et al. Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa. Bull World Health Organ. 2011;89:504–12. doi: 10.2471/BLT.11.085878.
    1. Kyaw SS, Drake T, Ruangveerayuth R, Chierakul W, White NJ, Newton PN, et al. Cost of treating inpatient falciparum malaria on the Thai-Myanmar border. Malar J. 2014;13:416. doi: 10.1186/1475-2875-13-416.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere